Table 4.
Indications for Semaglutide (As per American Diabetes Association 2020)
| Semaglutide | ||
|---|---|---|
| Efficacy | High | |
| Cost | High | |
| Oral/Injectable | Both available | |
| Weight loss | Yes | |
| Risk of Hypoglycaemia | No | Semaglutide monotherapy |
| Yes | Combination with insulin or other hypoglycaemic drugs; needs dose reduction | |
| Cardiovascular risk | Reduces cardiovascular risk | |
| Need for dose adjustment in geriatrics, renal and hepatic impairment | Not necessary | |
| Preferred conditions |
Requirement of greater glycaemic control Need for injectable therapy to reduce HbA1c Need to switch from injectable to oral therapy If possible, preferred over insulin In cardiovascular diseases of atherosclerotic origin and renal impairment Intolerance to SGLT-2 inhibitors Weight reduction is essential |
|
| Precautions |
Avoid in- Medullary carcinoma of thyroid, Pancreatitis, Multiple Endocrine Neoplasia Syndrome type 2, Progressive retinopathy, Congestive Heart Failure (As per EMA) |
|